Glucuronoxylomannan exhibits potent immunosuppressive properties.
about
Elucidating the immunological function of the Cryptococcus neoformans capsuleThe presence of 3-hydroxy oxylipins in pathogenic microbesSelf-aggregation of Cryptococcus neoformans capsular glucuronoxylomannan is dependent on divalent cationsBinding of the wheat germ lectin to Cryptococcus neoformans suggests an association of chitinlike structures with yeast budding and capsular glucuronoxylomannan.Spleen deposition of Cryptococcus neoformans capsular glucuronoxylomannan in rodents occurs in red pulp macrophages and not marginal zone macrophages expressing the C-type lectin SIGN-R1How sweet it is! Cell wall biogenesis and polysaccharide capsule formation in Cryptococcus neoformans.Cryptococcus neoformans capsular enlargement and cellular gigantism during Galleria mellonella infection.A major role for capsule-independent phagocytosis-inhibitory mechanisms in mammalian infection by Cryptococcus neoformans.A eukaryotic capsular polysaccharide is synthesized intracellularly and secreted via exocytosis.Multiple Disguises for the Same Party: The Concepts of Morphogenesis and Phenotypic Variations in Cryptococcus neoformansChitin-like molecules associate with Cryptococcus neoformans glucuronoxylomannan to form a glycan complex with previously unknown propertiesPhenotypic switching in Cryptococcus neoformans contributes to virulence by changing the immunological host responseCandida albicans: A Model Organism for Studying Fungal Pathogens.Systematic genetic analysis of virulence in the human fungal pathogen Cryptococcus neoformansThe capsule of the fungal pathogen Cryptococcus neoformans.Cryptococcus neoformans galactoxylomannan is a potent negative immunomodulator, inspiring new approaches in anti-inflammatory immunotherapy.Capsular Material of Cryptococcus neoformans: Virulence and Much More.A critical role for FcgammaRIIB in up-regulation of Fas ligand induced by a microbial polysaccharide.Immunomodulatory effects of serotype B glucuronoxylomannan from Cryptococcus gattii correlate with polysaccharide diameter.Structural and functional properties of the Trichosporon asahii glucuronoxylomannan.Cryptococcus neoformans inhibits nitric oxide synthesis caused by CpG-oligodeoxynucleotide-stimulated macrophages in a fashion independent of capsular polysaccharides.The Membrane Phospholipid Binding Protein Annexin A2 Promotes Phagocytosis and Nonlytic Exocytosis of Cryptococcus neoformans and Impacts Survival in Fungal Infection.Extracellular vesicles produced by Cryptococcus neoformans contain protein components associated with virulence.Role for chitin and chitooligomers in the capsular architecture of Cryptococcus neoformans.Fungal polysaccharides: biological activity beyond the usual structural properties.Binding of glucuronoxylomannan to the CD14 receptor in human A549 alveolar cells induces interleukin-8 production.Cryptococcus neoformans capsular polysaccharide and exopolysaccharide fractions manifest physical, chemical, and antigenic differences.Fungal Strategies to Evade the Host Immune Recognition.Immune Recognition of Fungal Polysaccharides.Cryptococcal pathogenic mechanisms: a dangerous trip from the environment to the brain.Glucuronoxylomannan promotes the generation of antigen-specific T regulatory cell that suppresses the antigen-specific Th2 response upon activation.A Predicted Mannoprotein Participates in Cryptococcus gattii Capsular Structure.Fungi as Sources of Polysaccharides for Pharmaceutical and Biomedical ApplicationsInvolvement of the capsular GalXM-induced IL-17 cytokine in the control of Cryptococcus neoformans infection
P2860
Q26859234-61FF3C83-519C-43BE-9C67-064DC1304484Q28395036-4BF210B9-6CDA-400B-A77C-68B290361CABQ30479935-B1FBCB78-5BA9-4155-809D-7758AA8F2326Q30481655-56AB4AD7-4E36-4767-B4E6-A2E288BAFFE8Q33687443-F47CE28F-E1E9-40D3-BA49-DABCE52D6170Q33894565-743CCF34-CDC9-489F-B92B-F1428C1BA54BQ34019066-894597B6-F6BF-483D-8CCF-59D999CBEE6EQ34798487-E545685E-F4A4-4C0F-8DA9-0DCBF16B4E8EQ35190974-D43C18C8-DCF9-469E-AAE6-FFC075620B0CQ35197055-E3336B2C-C45A-4D7E-B564-CBCB7B6C9B7CQ36244332-56199EBF-0CDF-495C-9E61-6C35BDFCCD77Q36845205-A4CD3193-E747-4F9F-890C-CBA4ECC15197Q36900101-7864A378-4551-4709-A3AC-E7E0BC500F17Q37066510-15FFF57E-AFB3-414F-A8EB-2B8646B34318Q37337879-F193592A-3EFB-4905-9728-FFAF492F75EAQ37917789-063F5D6F-45B2-486C-9119-59CA0EEA0EE6Q37982326-FD26CFC6-1A5E-4040-B631-E7274D9E6008Q39538013-C92A489E-0DC5-4DB9-8F5E-B4CFF6B0623DQ39693119-C851D374-A71C-4A29-80A1-D29653FE8912Q39873096-9D25763C-F7E0-43BC-8FBA-1874AC8A9FA4Q39993357-4936F7CF-0FB2-4ADF-98EA-4999771F47A6Q40627849-F84CD4D3-64FB-463E-802C-7FE0C92E5EB4Q41913077-E22E60D3-C388-4CE4-83FA-8DA16ECD5F07Q42017970-6D2BF89F-8A51-4C67-A816-0A87DD48F006Q42025211-10E75115-1737-430B-8500-4CABF5A8B055Q42956866-CAFE21AF-2906-4B0E-89F2-5B93D7032CBAQ43029434-EDC9CCF8-D489-48A2-A418-8995D24D5800Q48163110-79390A7D-950C-4555-9BB8-36BC56D6B514Q48163129-3B3EE9A5-8511-4BEF-81DA-D9691AFD0997Q52580472-308A73A5-F452-4408-A92F-D1D6AF43D657Q54439727-D0A02359-5AD3-4F06-9EE7-27F31A26AE84Q55220364-3F2E1D7C-3624-45CA-86DA-1EA473815C22Q58461452-546300D2-1705-4654-9B06-CC7C798E2F1BQ58608737-F22EFF35-297A-424E-933B-5EFCBEBA5E73
P2860
Glucuronoxylomannan exhibits potent immunosuppressive properties.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Glucuronoxylomannan exhibits potent immunosuppressive properties.
@ast
Glucuronoxylomannan exhibits potent immunosuppressive properties.
@en
type
label
Glucuronoxylomannan exhibits potent immunosuppressive properties.
@ast
Glucuronoxylomannan exhibits potent immunosuppressive properties.
@en
prefLabel
Glucuronoxylomannan exhibits potent immunosuppressive properties.
@ast
Glucuronoxylomannan exhibits potent immunosuppressive properties.
@en
P1433
P1476
Glucuronoxylomannan exhibits potent immunosuppressive properties
@en
P2093
Francesco Bistoni
P304
P356
10.1111/J.1567-1364.2006.00072.X
P577
2006-06-01T00:00:00Z